Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. T cells and oncology
3. Therapeutic use T cells
4. Therapeutic use of gene engeneered T cells (1)
5. Chimeric Antigen Receptors (CAR)
6. Anti-CD19 CAR T cells: clinical responses (1)
7. Anti-CD19 CAR T cells: clinical responses (2)
8. Anti-CD19 CAR T cells: clinical responses in diffuse large B cell lymphoma
9. Successful treatment with CAR T cells
10. F.D.A. approved treatment
11. Toxicities associated with CAR T cell therapy: Cytokine Release Syndrom (CRS)
12. Therapeutic use of gene engeneered T cells (2)
13. Therapeutic use of T cells: TCR vs. CAR (1)
14. Therapeutic use of T cells: TCR vs. CAR (2)
15. TCR vs. CAR: advantages and disadvantages
16. TCR vs. CAR: mode of action
17. Common effector molecules for CAR and TCR T cells
18. Issues associated with anti-CD19-CAR T cell therapies
19. Limited applicability of CAR T cells outside of hematological malignancies so far
20. The bottlenecks to CAR T cell therapy efficacy in solid tumors
21. Potential solutions - by means of engineering
22. Acknowledgements
23. Disclosures

Topics Covered

• Introduction to therapeutic use of T cells
• Clinical use of CAR T cell therapy
• CAR T cell therapy mode of action of
• Differences to TCR T cell therapy
• Resistance mechanisms to CAR T cell therapy

Links

Series:

• Periodic Reports: Advances in Clinical Interventions and Research Platforms

Categories:

• Cancer
• Cell Biology
• Diseases, Disorders & Treatments
• Pharmaceutical Sciences

Therapeutic Areas:

• Immunology & Inflammation
• Oncology

External Links

• Data files submitted to EMA for approval comparing anti-CD19 CAR T cell treatment in ALL with historical data from the CORAL trials.
• Data files submitted to EMA for approval comparing anti-CD19 CAR T cell treatment in DLBCL with historical data.

Talk Citation

Kobold, S. (2020, November 30). Mode of action of T cells engineered with CAR or TCR for cancer treatment [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 25, 2021, from https://hstalks.com/bs/4459/.

Publication History

• Published on November 30, 2020

Financial Disclosures

• Sebastian Kobold (S.K.) has licensed IP to TCR2 Inc, Boston. S.K. has received research support from TCR2 Inc and Arcus Biosciences. S.K. serves on the scientific advisory board of TCR2 Inc and on various scientific advisory boards of Novartis.